Shares of Emerald Bioscience Inc. (OTCMKTS:EMBI – Get Free Report) shot up 10.1% during trading on Wednesday . The company traded as high as $0.54 and last traded at $0.5194. 335,342 shares changed hands during trading, a decline of 98% from the average session volume of 14,236,620 shares. The stock had previously closed at $0.4717.
Emerald Bioscience Trading Up 10.1%
The company has a market cap of $139.24 million, a PE ratio of -6.49 and a beta of 0.43. The firm has a 50-day moving average price of $0.67. The company has a debt-to-equity ratio of 0.43, a quick ratio of 3.59 and a current ratio of 3.59.
Emerald Bioscience Company Profile
Emerald Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus.
Featured Articles
- Five stocks we like better than Emerald Bioscience
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Emerald Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emerald Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
